Who Owns Zoloft?
Zoloft is owned by Viatris Inc. (Nasdaq: VTRS), which acquired the brand in November 2020 when Pfizer spun off its Upjohn division and combined it with Mylan. Zoloft is the brand name for sertraline, an SSRI antidepressant approved by the FDA in 1991 for depression, obsessive-compulsive disorder, panic disorder, PTSD, social anxiety, and premenstrual dysphoric disorder. It was originally developed by Pfizer.
Parent Company
Acquired
2020
Status
Publicly Traded
Headquarters
Zoloft Timeline
Who Owns Zoloft?
- Parent Company: Viatris Inc.
- Ownership Type: Wholly owned
- Acquisition Year: 2020
- Company Type: Publicly Traded
- Stock Ticker: Nasdaq: VTRS
| Brand | Parent Company | Ownership Type |
|---|---|---|
| Zoloft | Viatris Inc. | Wholly owned |
Where to Buy
Disclosure: We may earn commission from purchases
Zoloft on AmazonAdvertisement
History of Zoloft
- Founded: 1991
- Founders: Pfizer (internal development)
- Acquired by Viatris Inc.: 2020
Pfizer scientists, led by the chemistry work of Kenneth Koe and Willard Welch, identified sertraline in the late 1970s while screening compounds that selectively blocked serotonin reuptake. The molecule offered the antidepressant effect of earlier drugs with fewer side effects, and Pfizer advanced it through clinical trials during the 1980s.
The FDA approved Zoloft on December 7, 1991, and it launched in the United States in 1992 as the third SSRI on the U.S. market after Prozac and Paxil. Zoloft eventually became the most prescribed antidepressant in the country, helped by label expansions covering panic disorder (1997), PTSD (1999), social anxiety disorder (2002), and premenstrual dysphoric disorder (2002).
Peak annual sales exceeded $3 billion in the mid-2000s. U.S. patent expiry in 2006 brought rapid generic competition and a steep revenue decline, the standard trajectory for blockbuster psychiatric brands. The trademark and remaining branded sales stayed with Pfizer until the Upjohn separation.
In November 2020, Zoloft transferred to Viatris as part of the Upjohn and Mylan combination. Under Viatris, the branded product continues to sell globally; in the first nine months of 2026 it produced $222.8 million in net sales, with particular strength in Greater China and emerging markets where the brand name retains substantial pricing power.
Advertisement
About Viatris Inc.
What does Viatris own?
Viatris owns the Lipitor, Viagra, Xanax, and Eliquis brands, along with a portfolio of over 1,400 approved generic molecules across cardiovascular, respiratory, central nervous system, oncology, immunology, and other therapeutic areas. The company also has a pipeline of complex generics and biosimilars. Its product portfolio was formed through the merger of Upjohn (Pfizer's legacy brand-name drug business) and Mylan (a global generic pharmaceutical company).
Is Viatris publicly traded?
Yes, Viatris Inc. is publicly traded on the Nasdaq stock exchange under ticker VTRS. The company has a dispersed shareholder base with institutional investors holding the majority of shares. Pfizer distributed its Viatris shares to Pfizer shareholders in 2021 and no longer holds a significant ownership stake. Viatris returned more than $1 billion to shareholders in 2025 through share repurchases and dividends.
Who founded Viatris?
Viatris was not founded by individuals. It was created in November 2020 through the merger of Upjohn, a division of Pfizer that held legacy brand-name drugs, and Mylan, a global generic pharmaceutical company founded in 1961 in White Sulphur Springs, West Virginia. The merger combined Upjohn's brand-name portfolio with Mylan's generic manufacturing capabilities to form a new company focused on providing access to affordable medicines.
Where is Viatris headquartered?
Viatris is headquartered in Canonsburg, Pennsylvania, USA. The company maintains its corporate offices in Pennsylvania and operates manufacturing facilities, distribution centers, and sales offices across the world. Its manufacturing network includes facilities in the United States, India, Europe, and China.
Advertisement
How many brands does Viatris own?
Viatris owns four key brand-name medicines: Lipitor, Viagra, Xanax, and Eliquis. The company also owns a portfolio of over 1,400 approved generic molecules across multiple therapeutic areas. In 2025, the company generated approximately $324 million in new product revenues and expects $450 million to $550 million in new product revenues in 2026 from its pipeline of generic and complex generic products.
Who owns Viatris?
Viatris is a publicly traded company with a dispersed shareholder base. Institutional investors, including mutual funds and investment firms, hold the majority of shares. No single shareholder has controlling ownership. Pfizer, the former parent of Upjohn, distributed its Viatris shares to Pfizer shareholders in 2021 and no longer holds a significant stake. The company is governed by a board of directors with independent representation.
What are Viatris's largest brands?
Lipitor and Viagra are Viatris's most recognizable brand-name products. Lipitor is a cholesterol-lowering statin medication originally developed by Pfizer. Viagra is an erectile dysfunction medication also originally developed by Pfizer. Xanax, an anti-anxiety medication, and Eliquis, an anticoagulant, are the company's other major brand-name products. Together, these brands contribute to the Developed Markets segment, which generated $8.5 billion in revenue in 2025.
- Founded: 2020
- Headquarters: Canonsburg, Pennsylvania, USA
- Company Type: Publicly Traded
- Stock: Nasdaq: VTRS
- Revenue: $14.3 billion (FY2025)
- Employees: approximately 32,000
Where Is Zoloft Made / Based?
- Headquarters: Canonsburg, Pennsylvania, USA
- Manufacturing / Operations: United States
Zoloft Categories & Tags
Zoloft Recalls & Controversies
Suicidality warnings: Zoloft, like all antidepressants, carries an FDA-mandated boxed warning about increased risk of suicidal thinking and behavior in children, adolescents, and young adults, added under the class-wide labeling requirement adopted in 2004.
Advertisement
Pregnancy litigation: Pfizer faced extensive product liability litigation alleging that Zoloft taken during pregnancy caused birth defects. Courts excluded the plaintiffs' expert evidence, and the federal multidistrict litigation was dismissed in 2016 in Pfizer's favor. The label carries standard pregnancy-use warnings.
Generic erosion and pricing: The brand's primary commercial controversy is structural rather than legal: branded Zoloft sells at a large premium to generic sertraline, a pricing model common to all post-patent pharmaceutical brands.
Brands Owned by Viatris Inc.
Healthcare PharmaceuticalsCelebrex
Owned by Viatris Inc.
Brand name for celecoxib, a COX-2 selective anti-inflammatory for arthritis and pain, owned by Viatris since the 2020 Upjohn merger. FDA approved in 1998.
anti-inflammatorynsaidarthritis
Healthcare PharmaceuticalsEpiPen
Owned by Viatris Inc.
Epinephrine auto-injector for severe allergic reactions, owned by Viatris since 2020. FDA approved in 1987 and the subject of major pricing controversy under former owner Mylan.
epinephrineauto-injectoranaphylaxis
Healthcare PharmaceuticalsLipitor
Owned by Viatris Inc.
Brand name for atorvastatin, the world's best-selling prescription drug from 1996 to 2012, generating over $125 billion in cumulative sales. Originally developed by Parke-Davis and acquired by Pfizer in 2000. Now owned by Viatris Inc. (NASDAQ: VTRS) since November 2020. FY2025 net sales of $1.55 billion.
cardiovascularcholesterolstatin
Healthcare PharmaceuticalsLyrica
Owned by Viatris Inc.
Brand name for pregabalin, a medication for neuropathic pain, fibromyalgia, and epilepsy. Originally developed by Pfizer, now owned by Viatris (NASDAQ: VTRS) following the 2020 Upjohn spinoff. US patent expired 2019.
pain-reliefneuropathic-painfibromyalgia
Healthcare PharmaceuticalsNorvasc
Owned by Viatris Inc.
Brand name for amlodipine, a once-daily calcium channel blocker for hypertension and angina, owned by Viatris since the 2020 Upjohn merger. FDA approved in 1992.
cardiovascularblood-pressurecalcium-channel-blocker
Healthcare PharmaceuticalsViagra
Owned by Viatris Inc.
Brand name for sildenafil citrate, the first oral erectile dysfunction treatment approved by the FDA in 1998. Originally developed by Pfizer, now owned by Viatris following the 2020 Upjohn spinoff and Mylan merger.
erectile-dysfunctionmens-healthprescription
Advertisement
Zoloft Ownership: Pros & Cons
Advantages
- +Viatris's emerging-market commercial network extracts continued value from the brand where generics are less dominant
- +Three decades of physician and patient familiarity sustain branded sales
- +Higher margins than the parent's generic portfolio support the branded-products strategy
- +Global regulatory and distribution infrastructure is centralized under one owner
Considerations
- -Most U.S. sertraline volume is generic, capping branded revenue potential
- -Boxed warning and pregnancy-safety history limit promotional flexibility
- -Pricing of post-patent brands attracts scrutiny in markets where generics are cheap
- -Long-term decline is structurally built into any off-patent brand
Frequently Asked Questions About Zoloft
Advertisement
Sources & Further Reading
Competitors to Zoloft
These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.
| Brand | Parent Company | Country | Founded | Market Position | Primary Market | Gender Target |
|---|---|---|---|---|---|---|
| Viatris | USA | 1981 | Premium | United states | All Genders | |
| Viatris | USA | 1998 | Premium | Global | All-ages | |
| Viatris | USA | 1987 | Premium | Global | All Genders | |
| Viatris | USA | 1996 | Premium | Global | All-ages | |
| Viatris | USA | 1992 | Mass market | Global | All-ages | |
| Viatris | USA | 2020 | Mass market | Global | All Genders |
Learn More About Competitors
Healthcare PharmaceuticalsXanax
Owned by Viatris Inc.
Brand name for alprazolam, the most prescribed benzodiazepine in the United States, owned by Viatris since the 2020 Upjohn merger. FDA approved in 1981 and a Schedule IV controlled substance.
anxietybenzodiazepineprescription
Healthcare PharmaceuticalsCelebrex
Owned by Viatris Inc.
Brand name for celecoxib, a COX-2 selective anti-inflammatory for arthritis and pain, owned by Viatris since the 2020 Upjohn merger. FDA approved in 1998.
anti-inflammatorynsaidarthritis
Healthcare PharmaceuticalsEpiPen
Owned by Viatris Inc.
Epinephrine auto-injector for severe allergic reactions, owned by Viatris since 2020. FDA approved in 1987 and the subject of major pricing controversy under former owner Mylan.
epinephrineauto-injectoranaphylaxis
Healthcare PharmaceuticalsLipitor
Owned by Viatris Inc.
Brand name for atorvastatin, the world's best-selling prescription drug from 1996 to 2012, generating over $125 billion in cumulative sales. Originally developed by Parke-Davis and acquired by Pfizer in 2000. Now owned by Viatris Inc. (NASDAQ: VTRS) since November 2020. FY2025 net sales of $1.55 billion.
cardiovascularcholesterolstatin
Healthcare PharmaceuticalsNorvasc
Owned by Viatris Inc.
Brand name for amlodipine, a once-daily calcium channel blocker for hypertension and angina, owned by Viatris since the 2020 Upjohn merger. FDA approved in 1992.
cardiovascularblood-pressurecalcium-channel-blocker
Healthcare PharmaceuticalsViatris
Owned by Viatris Inc.
Corporate brand of Viatris Inc., the global pharmaceutical company formed in 2020 from the merger of Pfizer's Upjohn division and Mylan, selling medicines in more than 165 countries.
pharmaceuticalsgenericsbranded-generics
Competitive Analysis
Market Positioning: Zoloft competes with 6 brands in the same categories, ranging from mass market to luxury positioning.
Geographic Distribution: Competitors are headquartered across multiple regions, indicating global competition in this market segment.
Brand Heritage: Competitor brands range from established heritage brands to newer market entrants, with founding years spanning several decades.
Advertisement
Independent Alternatives to Zoloft
Looking for brands with different ownership structures? These similar brands are not owned by Viatris Inc., giving you alternative choices that support different corporate structures.
Healthcare PharmaceuticalsGE HealthCare
Owned by GE HealthCare Technologies Inc.
Independent publicly traded healthcare technology company spun off from General Electric in January 2023, providing medical imaging, diagnostics, and healthcare IT solutions globally.
healthcare-technologymedical-imagingdiagnostics
Publicly Traded
GE HealthCare operates independently without a large parent corporation.
Healthcare PharmaceuticalsHCA Healthcare
Owned by HCA Healthcare, Inc.
HCA Healthcare is the flagship brand of the largest U.S. for-profit hospital operator, a network of 190 hospitals and about 2,500 ambulatory sites across 19 states and England.
hospitalshealthcareemergency-care
Publicly Traded
HCA Healthcare operates independently without a large parent corporation.
Healthcare PharmaceuticalsPfizer
Owned by Pfizer Inc.
American multinational pharmaceutical corporation developing and manufacturing medicines, vaccines, and consumer healthcare products, one of the world's largest pharmaceutical companies.
pharmaceuticalvaccinesmedicines
Publicly Traded
Pfizer operates independently without a large parent corporation.
Healthcare PharmaceuticalsPhilips
Owned by Koninklijke Philips N.V.
Health technology brand owned by Koninklijke Philips N.V., a publicly traded Dutch company listed on Euronext Amsterdam (PHIA). Covers medical imaging, patient monitoring, and personal health products.
healthcare-technologyelectronicsmedical-devices
Publicly Traded
Philips operates independently without a large parent corporation.
Healthcare PharmaceuticalsRegeneron
Owned by Regeneron Pharmaceuticals, Inc.
Biotechnology brand of Regeneron Pharmaceuticals, developer of Eylea, Dupixent, and Libtayo, headquartered in Tarrytown, New York.
biotechnologypharmaceuticalseylea
Publicly Traded
Regeneron operates independently without a large parent corporation.
Healthcare PharmaceuticalsTirosint
Owned by IBSA Institut Biochimique S.A.
IBSA Institut Biochimique SA's branded levothyroxine softgel capsule (Tirosint) and liquid solution (Tirosint-SOL), FDA approved for hypothyroidism, formulated without dyes, gluten, lactose, alcohol, or sugar, providing an excipient-free alternative to conventional levothyroxine tablets for patients with sensitivities or absorption issues.
levothyroxinehypothyroidismthyroid
Privately Owned
Tirosint is privately owned, unlike Zoloft which is under a publicly traded parent company.
Viatris Inc. Stock Information
Advertisement
Jobs at Viatris Inc.
Latest News About Zoloft
Advertisement
Related Articles About Zoloft
View more articles
News & Updates
Monthly M&A Roundup: October 2026 Brand Ownership Changes
October 2026's biggest deals: Paramount Skydance closed its $110B Warner Bros. Discovery takeover, Salesforce signed Braze for $5.66B, Proofpoint bought Varonis for $6.3B, the Weston family agreed to buy Boots for $8.9B, and Viatris added Pacira for $1.65B. Full breakdown.
Who Brands StaffNov 6, 2026
M And A RoundupAcquisitionsNews
News & Updates
Monthly IPO Roundup: November 2026 -- October's Biggest Listings
October 2026 IPOs: Jio Platforms set India's all-time record at $3.2B and surged 27%, GCash owner Mynt raised a Philippine-record P60.9B, Anthropic filed publicly for a possible mid-November debut, and U.S. listings were a biotech grab bag. Full recap.
Who Brands StaffNov 6, 2026
Ipo RoundupIpoStock Market
Rivalry
Duracell vs Energizer: The Battery Brand Rivalry
Duracell is Berkshire Hathaway-owned (25-30% US share). Energizer is publicly traded (NYSE: ENR) with Rayovac. Together they control ~85% of branded US batteries, but Amazon Basics has 27.1% online. Explore our database.
Who Brands StaffOct 23, 2026
DuracellEnergizerRivalry
People Also Searched
Discover popular brands and companies in the Healthcare & Pharmaceuticals category and related searches from other users.
Brandpharmaceutical
Abbokinase
Abbokinase (urokinase) is a thrombolytic medication historically used for pulmonary embolism and catheter clearance. Originally marketed by Abbott Laboratories, now owned by Microbix Biosystems as Kinlytic. FDA-approved since 1978.
Brand in Healthcare & Pharmaceuticals
thrombolyticurokinase
Brandrsv-vaccine
Abrysvo
Pfizer's respiratory syncytial virus (RSV) vaccine approved for older adults, maternal immunization to protect infants, and younger at-risk adults. Launched 2023.
Brand in Healthcare & Pharmaceuticals
vaccinesmaternal-immunization
Branddermatology
Accutane
Prescription isotretinoin brand developed by Roche and approved by the FDA in 1982 for severe nodular acne. Roche discontinued the brand name in the United States in 2009; the drug continues as Roaccutane in international markets.
Brand in Healthcare & Pharmaceuticals
acne-treatmentprescription